BioWorld

Feb. 10, 2009

Lundbeck Gains U.S. Foothold in $900M Deal for Ovation

Danish drugmaker H. Lundbeck A/S plans to buy U.S. biotech Ovation Pharmaceuticals in a proposed $900 million deal that would give the Copenhagen-based company access to the U.S. commercial market. (BioWorld Today) Read More

Investors Seeing Positive Side for Biotech in Bleak Economy

Panel: Keep Options Open to Survive Troubled Times

ViroPharma Shares Halved as Maribavir Fails Phase III Trial

Alliance Management Plays Important Role in Avoiding Failure

Lobbying Dynamics Reveal New Trends in Power

Gilded Age Can Be Ushered in by Biopartnered Gene Therapies

Corrections & Clarifications

Dynavax Soars on Possibility of Regulatory Path for Heplisav

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

EASL 2026: Emerging liver disease targets to watch

BioWorld

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...